Drug toxicity often goes undetected until clinical trials, the most costly and dangerous phase of drug development. Both the cultures of human cells and animal studies have limitations that cannot be overcome by incremental improvements in the drug testing protocols. A new generation of preclinical models - in form of integrated human tissue platforms, would be transformative to drug screening and predictive modeling of disease. This multiphase (UH2/UH3) proposal integrates in a novel and synergistic way some recent breakthroughs from four leading laboratories, towards developing a vascular/liver/cardiac microtissue system predictive of integrated human physiology. In the UH2 phase, we aim to establish iPS-based vascular, liver and cardiac microtissues providing (i) hierarchical tissue-specific architectures, (ii) functional representation of human biology of health, injury and disease, (iii) real-time biological readouts, and (iv) compatibility with high-throughput/high-content multi-tissue platforms for studies of drug toxicity and over long periods of time (e4 weeks). The work will be done using iPS-derived cells (to provide a large diversity of normal and disease genotypes) and using nondestructive monitoring of the tissue architecture and function (to provide real-time insights into the progression of cell and tissue responses). Our overall hypothesis is that tissue specific structure-function relationship can be achieved through control and biomimetic application of microenvironemental cues in vitro. Such microtissues will then be high-fidelity models for drug testing and toxicology. In the UH3 phase we aim to deploy an integrated cardiac/hepatic/vascular platform and demonstrate its utility for a broad range of genotypes and drugs. Towards these goals, we will pursue a set of coordinated aims with constant feedback, evaluation, and monitoring of the milestones.
Aim 1 is to develop cell-type specific labeling and sensing systems for on-line assessment of tissue architecture and cell function.
Aim 2 is to develop a perfusable branching vascular network serving as a model of the vascular bed and for assembling vascularized liver and cardiac tissues.
Aim 3 is to develop a liver module by assembling hepatic microtissues in hydrogel around the vascular tree.
Aim 4 is to develop a cardiac module by assembling matured cardiac microtissues in hydrogel around the vascular tree.
Aim 5 is to conduct studies of disease susceptibility, for the individual tissue modules and in the multi-tissue platform.
Aim 6 is to investigate human physiology and disease in multi-tissue platforms. This way, we aim to develop a radically new technology for studies of drugs in human tissue models. If successful, the proposed approach would radically enhance the translation of drug discovery into human applications, by enabling accurate preclinical data for better, faster and cheaper clinical trials.
Broader Impact We propose to engineer three different microtissues highly resembling the structure and normal function of human capillary network, liver lobule and heart muscle, and to use these microtissues for screening of drugs and study of disease under conditions representative of whole bodyphysiology. To enable personalized approach to evaluation of drug regimens and study of disease, we will use adult stem cells derived from small samples of the patient's skin. This technology could greatly accelerate translation of discovery into new therapeutic modalities for the patients in need.
|Logan, David J; Shan, Jing; Bhatia, Sangeeta N et al. (2016) Quantifying co-cultured cell phenotypes in high-throughput using pixel-based classification. Methods 96:6-11|
|Ogle, Brenda M; Bursac, Nenad; Domian, Ibrahim et al. (2016) Distilling complexity to advance cardiac tissue engineering. Sci Transl Med 8:342ps13|
|Wobma, Holly; Vunjak-Novakovic, Gordana (2016) Tissue Engineering and Regenerative Medicine 2015: A Year in Review. Tissue Eng Part B Rev 22:101-13|
|Lee, Benjamin W; Liu, Bohao; Pluchinsky, Adam et al. (2016) Modular Assembly Approach to Engineer Geometrically Precise Cardiovascular Tissue. Adv Healthc Mater 5:900-6|
|Villasante, Aranzazu; Marturano-Kruik, Alessandro; Ambati, Srikanth R et al. (2016) Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. Theranostics 6:1119-30|
|Schepers, Arnout; Li, Cheri; Chhabra, Arnav et al. (2016) Engineering a perfusable 3D human liver platform from iPS cells. Lab Chip 16:2644-53|
|Feric, Nicole T; Radisic, Milica (2016) Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Adv Drug Deliv Rev 96:110-34|
|Parsa, Hesam; Ronaldson, Kacey; Vunjak-Novakovic, Gordana (2016) Bioengineering methods for myocardial regeneration. Adv Drug Deliv Rev 96:195-202|
|Eng, George; Lee, Benjamin W; Protas, Lev et al. (2016) Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes. Nat Commun 7:10312|
|Kutys, Matthew L; Chen, Christopher S (2016) Forces and mechanotransduction in 3D vascular biology. Curr Opin Cell Biol 42:73-79|
Showing the most recent 10 out of 38 publications